Levonorgestrel-releasing intrauterine system as an adjunct to estrogen for the treatment of menopausal symptoms-a review

Menopause

Volumn 14, Issue 3, 2007, Pages 550-554

  Peled, Yoav ^a   Perri, Tamar ^a   Pardo, Yosef ^a   Kaplan, Boris ^a  

^a NONE

Author keywords

Intrauterine system; Levonorgestrel; Menopausal symptoms

Indexed keywords

ESTRADIOL; LEVONORGESTREL; PROGESTERONE DERIVATIVE;

ESTROGEN THERAPY; FEMALE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MENOPAUSE; METABOLISM; METHODOLOGY; REVIEW;

ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MENOPAUSE; PROGESTERONE CONGENERS;

EID: 34447258647     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/01.gme.0000247013.62092.1c     Document Type: Review

References (38)

1. The North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003;10:113-132.
2. Gambrell RD Jr. Prevention of endometrial cancer with progestogens. Maturitas 1986;8:159-168.
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
4. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
5. Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003;97:1387-1392.
6. Speroff L, Fritz MA. Post menopausal hormone therapy. In: Speroff L, Fritz MA, eds. Clinical Gynecologic Endocrinology and Infertility, 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:689-777.
7. Whitehead M. Treatments for menopausal and postmenopausal problems: present and future. Baillieres Clin Obstet Gynaecol 1996;10:515-530.
8. Akkad AA, Habiba MA, Ismail N, et al. Abnormal uterine bleeding on hormone replacement: the importance of intrauterine structural abnormalities. Obstet Gynecol 1995;86:330-334.
9. Jia M, Zhou L, Ren S, et al. Serum SHBG levels during normal menstrual cycle and after insertion of levonorgestrel-releasing IUD. Adv Contracept 1992;8:33-40.
10. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol 1982;17:529-536.
11. Suhonen S, Holmström T, Allonen HO, Lähteenmäki P. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril 1995;63:336-342.
12. Raudaskoski T, Tapanainen J, Tomas E, et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002;109:136-144.
13. Boon J, Scholten PC, Oldenhave A, Heintz AP. Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT. Maturitas 2003;25:69-77.
14. Sturdee DW, Rantala ML, Colau JC, et al, for the Multicenter MLS Investigators. The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women. Climacteric 2004;7:404-411.
15. Wildemeersch D, Janssens D, Weyers S. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination? Maturitas 2005;51:207-214.
16. Hampton NR, Rees MC, Lowe DG, et al. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005;20:2653-2660.
17. Andersson K, Mattsson LA, Rybo G, et al. Intrauterine release of levonorgestrel-a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992;79:963-967.
18. Suhonen SP, Holmstrom T, Lahteenmaki P. Three-year follow-up of the use of a levonorgestrel-releasing system in hormone replacement therapy. Acta Obstet Gynecol Scand 1997;76:145-150.
19. Raudaskoski TH, Lahti EI, Kauppila A, et al. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995;156:1332-1334.
20. Suvanto-Luukkonen E, Sundstrom H, Penttinen J, et al. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas 1997;26:211-217.
21. Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001;76:969-973.
22. Warming L, Ravn P, Skouby S, et al. Measurement precision and normal range of endometrial thickness in a postmenopausal population by transvaginal ultrasound. Ultrasound Obstet Gynecol 2002;20:492-495.
23. Goldstein SR. Endometrial safety during hormone replacement therapy: comparison of transvaginal sonography and endometrial biopsy. Menopause 1998;5:132-133.
24. Langer RD, Pierce JJ, O'Hanlan KA, et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Intervention Trial. N Engl J Med 1997;337:1792-1798.
25. Sturdee D. The levonorgestrel-releasing intrauterine system (Mirena®) in the peri- and postmenopause. Gynaecol Forum 2006;11:25-27.
26. Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005;106:813-817.
27. Lundstrom E, Soderqvist G, Svane G, et al. Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study. Fertil Steril 2006;85:989-995.
28. Raudaskoski TH, Tomás EI, Paakkari IA, et al. Serum lipids and lipoproteins in post-menopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device. Maturitas 1995;22:47-53.
29. Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod 2005;20:789-793.
30. Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992;166:950-955.
31. Walsh JM, Grady D. Treatment of hyperlipidemia in women. JAMA 1995;11:1152-1158.
32. Bass KM, Newschaffer CJ, Klag MJ, et al. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;11:2209-2216.
33. Andersson K, Stadberg E, Mattsson LA, et al. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women-effects on lipid metabolism during 12 months of treatment. Int J Fertil Menopausal Stud 1996;41:476-483.
34. Barrett-Conner E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk in the 1980s. JAMA 1989;261:2095-2100.
35. Gambrell RD Jr, Teran AZ. Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy. Am J Obstet Gynecol 1991;165:307-317.
36. Nabulski AA, Folsum AR, White A, et al. Association of hormone replacement therapy with various cardiovascular factors in postmenopausal women. N Engl J Med 1991;328:1069-1076.
37. Nilsson CG, Kostiainen E, Ehnholm C. Serum lipids and high-density lipoprotein cholesterol in women on long-term sustained low-dose IUD treatment with levonorgestrel. Int J Fertil 1981;26:135-137.
38. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56-72.